BrandTech Scientific Titrette®

The Titrette® is the new generation of bottletop burette from BRAND. It has a number of innovative features and upgrades for more accurate and convenient titration.

By | January 3, 2014

Request More Information

BrandTech® proudly introduces a new 10mL size of BRAND® Titrette® bottletop burette. This new size provides unparalleled performance, meeting the tolerance limits for 10mL Class A glass burettes per ASTM and DIN EN ISO 285. This new model has all of the safety and convenience features as the 25mL and 50mL members of the Titrette family, such as a low profile design, adjustable titrating tube, recirculation valve for priming, and total disassembly for easy cleaning and servicing. Included amber windows help protect light sensitive titrants. An optional RS232 computer interface eliminates transcription error. Details are available at www.BrandTech.com .

Request More Information

Product Details

BrandTech Scientific Titrette

image of: BrandTech Scientific Titrette

Titrette® Bottletop Burette

Request More Information

Your Request
About You
Enter text from the image above:

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham